Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

MRD-seq: A sensitive next generation sequencing-based approach for measurable residual disease detection in acute myeloid leukaemia

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMariam AlhilaliBlood Cancer UKPBPeter BrowettUniversity of AucklandSBStefan K. BohlanderUniversity of Auckland

Discussion

Loading...

Member takes

Overview

Next generation sequencing detects measurable residual disease in acute myeloid leukaemia, indicating improved therapeutic efficacy and disease management strategies.

Key Points

  • Assess the effectiveness of next generation sequencing for detecting measurable residual disease in acute myeloid leukaemia.
  • Developed MRD-Seq for sensitive, mutation-specific detection
  • Validated assays for NPM1 Type A and IDH1R132H mutations
  • Utilized unique molecular identifiers for error detection
  • Conducted tests using serial dilution of cell lines
  • Achieved sensitivity of 1 × 10⁻⁵ for NPM1 Type A mutation
  • Showed sensitivity of 1 × 10⁻³ for IDH1R132H mutation
  • MRD-Seq comparable in sensitivity to qualitative PCR assays
  • Adaptable to various somatic mutations with minimal reconfiguration

Cite This Study

Alhilali et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d54ahttps://doi.org/10.1182/blood-2025-7046
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Monitoring of measurable residual disease by next‐generation sequencing in patients with acute myeloid leukaemia2025 · 5 citations
  2. 2A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia2025 · 2 citations
  3. 3Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation2026
  4. 4Advances in measurable residual disease assessment for acute myeloid leukemia: from cytogenetics and molecular biology to assessment of the methylation pattern and surface-enhanced Raman scattering as emerging technologies2025 · 3 citations
  5. 5Comparative evaluation of NGS-based MRD detection in AML using longitudinal matched bone marrow and blood samples2025